UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): December 6, 2005
BODISEN BIOTECH, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 333-99101 98-0381367
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
North Part of Xinquia Road, Yang Ling Agricultural High-Tech
Industries Demonstration Zone, Yang Ling, People's Republic
of China 712100
(Address of principal executive offices) (Zip Code)
86-29-87074957
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On December 6, 2005, Bodisen Biotech, Inc. (the "Company") will issue a
press release announcing record earnings for the quarter ended December 31,
2005. A copy of the press release is furnished herewith as Exhibit 99.1 and is
incorporated herein by reference.
This Report on Form 8-K is being furnished pursuant to Item 2.02, Results
of Operations and Financial Condition. The information furnished is not deemed
"filed" for purposes of the Securities Exchange Act of 1934, as amended, is not
subject to the liabilities of that section and is not deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended.
Item 8.01 Other Events.
On December 6, 2005, the Company will issue a press release regarding
earnings guidance for fiscal year 2006. A copy of this guidance is included in
the press release attached as Exhibit 99.1 and is incorporated herein by
reference.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits
Exhibit 99.1 Press Release, dated December 6, 2005
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BODISEN BIOTECH, INC.
/s/ Qiong Wang
Date: December 6, 2005 --------------
Qiong Wang,
Chief Executive Officer
3
EXHIBIT INDEX
Exhibit Number Description Method of Filing
---------------------------------------------------------------------------------------------------------------------
99.1 Press Release dated December 6, 2005 captioned "Bodisen Filed herewith as Exhibit 99.1
Biotech Signs US$43 Million in Contracts, Sees Record
Earnings for 2006 and Continued Favorable Market
Environment; Company Updates Growth Strategies for 2006"
4